Celer Diagnostics, a company that develops fast and cost-effective cancer diagnostic kits based on extracellular vesicles (EVs). EVs are membrane-bound nanoparticles that carry bioactive molecules such as proteins, lipids, and nucleic acids. EVs can be isolated from blood samples and used as biomarkers for various diseases, including cancer.
In this article, we want to share with you some of the advantages of using EVs over cells for cancer diagnosis. Here are some of the reasons why EVs are better than cells:
- EVs are more abundant and stable than cells in blood samples. Cells can be easily damaged or degraded by mechanical stress, enzymatic activity, or immune response. EVs, on the other hand, are protected by their lipid bilayer and can survive longer in circulation.
- EVs are more representative and informative than cells for cancer status. Cells may not reflect the heterogeneity and dynamics of the tumor microenvironment. EVs, however, can capture the molecular profile and functional state of the tumor cells and their interactions with other cells. EVs can also carry genetic mutations and epigenetic modifications that are relevant for cancer diagnosis and prognosis.
- EVs are easier and cheaper to isolate and analyze than cells for cancer detection. Cells require complex and expensive methods for isolation, purification, culture, and characterization. EVs can be isolated by simple and low-cost techniques such as centrifugation, filtration, or precipitation. EVs can also be analyzed by various methods such as flow cytometry, mass spectrometry, or next-generation sequencing.
These are some of the reasons why we at Celer Diagnostics believe that EVs are better than cells for cancer diagnosis. We have developed Celer Kits, which are fast and cost-effective EV-based diagnostic kits that observe 7 biometrics in patients’ blood samples and derive reliable results. With just a 5cc blood sample and in less than 2 hours, Celer Kits can obtain accurate results, detecting breast cancer at early stages.
If you are interested in learning more about our products and services, please visit our LinkedIn or contact us at info [@] celerdiagnostics.com. We would love to hear from you and answer any questions you may have.
2 Responses
I was wondering, whether your procedure has FDA approval? and is it implemented only in breast cancer?
Thank you for reaching out. To clarify, the process is not yet FDA-approved, as FDA certification is a complex, time-consuming process that requires several stages of validation.
Regarding your second question, the answer is no. The process can be used for detecting any protein markers associated with extracellular vesicles (EVs) in liquid biopsies, regardless of their source. The origin of the EVs is not crucial to the detection method.